StockWatch
·

Blue Jet Healthcare Ltd Q2 FY27 Results

BLUEJETQ2 FY27 Results
Filing
Result:Good· Market: Surged#Base effect#Margin squeeze

Outlook: Cautiously Optimistic · Guidance: Maintained

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue375.7428.2%127.1%
Total Income401.9530.4%111.8%
Expenditure264.5630.7%118.6%
PBT137.3929.7%99.9%
Net Profit102.5231.0%96.6%
OPM31.60%1.86pp1.61pp
NPM25.50%0.12pp1.98pp
EPS5.4621.1%81.4%
View full financials

Pharma/CDMO core growth is strong (revenue +127% YoY, PAT +97%) but EBITDA margin compressed to 31.6% from 33.2% YoY on a favorable inventory-change base effect last year, keeping this healthy-but-not-standout rather than very_good.

BLUE JET HEALTHCARE · Q2 FY27 · THE VERDICT

Record Growth, Margin Compression—and Silence on Outlook

Blue Jet delivered 127% YoY revenue growth and 97% PAT growth, but West Asia raw-material inflation compressed gross margin by 400 basis points. Management refuses forward guidance, citing CDMO unpredictability.

12 Nov 2026 · 6 min read
Q2 Revenue

₹375.7 Cr

+127% YoY, +28.2% QoQ

Gross Margin

49%

Down 400 bps QoQ from ~53%

Q2 PAT

₹102.5 Cr

+96.6% YoY, +31% QoQ

EBITDA

₹119 Cr (32%)

Held despite margin headwind

On the headline, Blue Jet looks like a blowout: 127% revenue growth and 97% PAT growth anchor a quarter that screams execution. But open the call and the story shifts. Gross margin compressed 400 basis points quarter-on-quarter, driven by West Asia raw-material inflation on resins, reagents, and solvents. More tellingly, management refused to quantify forward guidance—the CFO said 'very hard to give about sustainability,' and the COO declared 'impossible for anyone to give that type of guidance' on CDMO business. That silence, after such explosive numbers, is the real tension the quarter lays bare: exceptional near-term growth anchored to a business that refuses to forecast, with margin recovery pending customer pricing negotiations that may or may not close in Q3.

Where the profit came from

The reported profit is clean—no MTM gains or tax reversals. EBITDA of ₹119 Cr (31.7% of operating revenue) sits just below the headline, and PAT of ₹102.5 Cr (27.3% of total income) leans on operational leverage even as gross margin fell. The real story is cost absorption: BJHL held EBITDA margin at 32% quarter-on-quarter despite a 400-basis-point gross margin hit, implying OpEx and cost of sales management was disciplined enough to offset raw-material headwind.

Q2 FY27, ₹ Cr
0140.37280.75421.12376Revenue119EBITDA102PAT
Revenue growth exceptional; PAT margin at 27%, held via cost discipline despite gross margin compression.

Claims vs. what holds up

Management's on-call assertions: audit trail

Q2 revenue ~₹376 Cr with 28% QoQ growth

What holds up

Delivered ₹375.7 Cr, 28.2% QoQ; H1 FY27 ₹669 Cr at 29% YoY

Verdict

Supported

EBITDA 32% of operating revenue, PAT 27% of income

What holds up

EBITDA ₹119 Cr = 31.7%; PAT ₹102.5 Cr = 27.3% of total income

Verdict

Supported

Gross margin 49%, down 4% QoQ; raw material inflation from West Asia

What holds up

OPM 31.6%; margin compression to 49% from ~53% QoQ verified; West Asia cost drivers acknowledged

Verdict

Supported

Mahad Unit 3 ~₹250 Cr capex, on stream H2; Vizag end FY29–FY30

What holds up

₹250 Cr YTD capex reaffirmed; timeline unchanged. Backward integration for KSM contract media confirmed

Verdict

Supported

Contrast media intermediate delivered; peptide, CNS, cardiovascular in development

What holds up

New molecules now in commercial/validation phases (vs prior 'not significant'); Q2 included commercial batches

Verdict

Slightly overstated—revenue still immaterial; framed as 'encouraging' but unquantified

Strong order book and sequential ramp-up evident over 3–4 quarters

What holds up

PI vertical and CDMO segments cite 'good visibility'; no customer names or forward quantification

Verdict

Supported but opaque—no forward guidance provided

What changed on this call

Key shifts vs. prior FY27 call
  • New product maturity upgraded: CNS and cardiovascular now in commercial/validation phases (vs. prior 'not significant' validation batches only). Q2 included commercial quantities.

  • Gross margin compressed: 49% vs. ~53% prior quarter. Prior call implied stability; West Asia cost spike drives near-term pressure. Recovery dependent on Q3 pricing pass-through acceptance.

  • Capex and Vizag timeline reaffirmed: Mahad Unit 3 ~₹250 Cr YTD, on track H2 stream. Vizag Phase 1 ₹1,000 Cr, commercialization end FY29–FY30. No acceleration or delay.

  • Forward guidance deflection: Management refused to quantify Q3+ revenue or margin targets, citing CDMO business unpredictability. Unprecedented for a ₹376 Cr revenue company with stated 'good order visibility.'

How the street is positioned

The stock sits at ₹535.75, off its all-time high of ₹1,027.8 (−47.87%) and trading below its 50-day moving average of ₹542.63 but above the 200-day at ₹489.64. Price trend is neutral; RSI at 51.5 signals no directional conviction. Volume is increasing, a positive signal on institutional re-engagement.

Ownership is shifting: FII holdings fell 135 basis points year-to-date (1.97% in Q1 FY26 → 0.62% in Q2 FY27), a notable retreat. DII holdings rose 447 basis points quarter-on-quarter (4.65% → 9.12%), suggesting domestic institutions are building. Promoter stake trimmed 666 basis points QoQ (79.81% → 73.15%), a swing that reflects the ₹800 Cr qualified institutional placement (QIP) raise announced for capex funding. The QIP itself is a capital discipline signal—BJHL is funding ₹250 Cr Mahad capex and Vizag Phase 1 groundwork from equity, not debt.

The broad picture: FII retreat suggests overseas investors are uncomfortable with the guidance opacity and margin headwind; DII accumulation indicates domestic players see value in the CDMO capex thesis. The drawdown from ATH to −47.87% has reset sentiment, but the stock's trading below the 50-day average implies the post-result relief rally (if any) has already faded.

The bull-bear ledger

  • Exceptional 127% YoY revenue growth driven by CDMO platform ramp and first-time new product contributions.

  • PAT growth of 97% YoY demonstrates operational leverage even with margin compression.

  • Capex execution strong: Mahad Unit 3 ₹250 Cr YTD on track for H2 stream; backward integration for KSM contract media locked in.

  • Gross margin compressed 400 bps QoQ (49% vs. ~53%) due to West Asia raw-material inflation; recovery timing and magnitude uncertain.

  • Management deflected on forward guidance despite strong order book; refuses to quantify revenue or margin targets ('very hard to give sustainability').

  • New product contribution rising but immaterial; CNS, cardiovascular, peptide fragments still in validation/early commercial phases.

  • Vizag ₹1,000 Cr capex (Phase 1) won't drive material revenue until end FY29–FY30 (3+ years); execution and regulatory risk present.

  • FII ownership retreated 135 basis points YTD; domestic institutions building positions; promoter trimmed 666 bps QoQ for capex funding.

Ranked risks—what should concern a holder

Concerns ranked by severity and impact on thesis

Gross margin compression (49% from 53%, 400 bps QoQ)

High

Q3 pricing pass-throughs may not fully offset West Asia cost spike. If recovery delayed, margin stays depressed into Q4, eroding Q2–Q3 PAT growth visibility. CFO acknowledged reagent/solvent costs 'cannot pass 100%' to customers.

Forward guidance opacity

High

Management won't quantify revenue or margin targets, claiming CDMO business makes forecasting 'impossible.' Makes quarter-to-quarter tracking opaque; valuation becomes event-driven (beat/miss cycles) rather than model-driven. Raises questions on management's own confidence.

New product revenue immateriality

Medium

CNS, cardiovascular, peptide fragments, contrast media intermediate now in commercial/validation phases, but Q2 contribution negligible vs. ₹376 Cr base. If ramp-up lags, growth deceleration risk in outer years when CDMO mature phase winds down.

Vizag capex execution (₹1,000 Cr, 3+ years to commercialization)

Medium

Long-dated execution window (end FY29–FY30); regulatory approvals (Environmental Clearance, land consent) required; cost/timeline slippage possible. Phase 1 includes high-intensity sweetener and peptide fragments—portfolio not yet de-risked.

Product and customer concentration

Medium

Contrast media flat ~$55 Mn for 3 years; KSM sweetener concentrates Vizag growth plan. Customer names not disclosed. If major customer program delays, growth outlook volatile.

FII ownership retreat

Low-Medium

FII stakes down 135 bps YTD; suggests overseas investors uncomfortable with guidance opacity and margin headwind. Could signal risk re-assessment by foreign institutions; may limit upside valuation support.

The debate

What to watch next
  • 1 · Q3 gross margin recovery

    This is the linchpin. Management expects pricing pass-throughs to take effect in Q3. If Q3 gross margin bounces back toward 52%+ (restoring the 400 bps compression), credibility in management's 'recovery expected' messaging holds. If it stays near 49%, the bear case (structural margin pressure) gains traction.

  • 2 · Mahad Unit 3 stream-up in H2 FY27

    Backward integration for KSM contract media is the near-term capex win. On-time H2 delivery (Oct–Mar 2027) will de-risk Vizag Phase 1 and demonstrate operational discipline. Delay signals potential slippage on Vizag.

  • 3 · New product commercialization timeline

    CNS, cardiovascular, peptide fragments, and contrast media intermediate are in validation/early commercial phases. Q3–Q4 FY27 commentary on volume ramp-up (even unquantified) will indicate whether 'encouraging' is turning into material. Early revenue signals will validate the new product thesis.

  • 4 · Forward guidance disclosure

    Management's continued refusal to quantify revenue/margin targets is a red flag. If Q3 call continues to deflect, market will price in execution risk premium. Any guidance (even conservative) in Q3 would reset sentiment.

Blue Jet Healthcare delivered a headline quarter that belies underlying tension. The 127% revenue growth is real; the capex execution is solid. But gross margin compression and management silence on forward outlook signal near-term risk. The stock has reset sharply from ATH, and DII accumulation at lower prices is constructive—but overseas investors are waiting for proof. The honest read is steady execution, not a step-change. The number to track from here is Q3 gross margin: a return to 52%+ validates management's pricing-recovery thesis; a stay near 49% warns of structural margin pressure that the market has yet to price in. Capex delivery (Mahad H2 stream-up) and new product progress are secondary confirmations. Hold on fundamentals, but with conviction contingent on margin recovery and visibility.

Informational and educational content only. Not investment advice.